Concepedia

Publication | Open Access

Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction

DOIFull Paper Access

69

Citations

19

References

2017

Year

John J.V. McMurray, David Trueman, Elizabeth Hancock, Martín Cowie, Andrew Briggs, Matthew Taylor, J. Mumby-Croft, Fionn Woodcock, Michael J. Lacey, R Haroun,
Heart

Abstract

Our analysis suggests that, in all three countries, sacubitril/valsartan is likely to be cost-effective compared with an ACEI (the current standard of care) in patients with HF-REF.

References

YearCitations

Page 1